CEO Tim Tangredi of Dais Analytic Corporation, rejoins Stock Day to talk about services and products for the energy and water industry revolving.
Flux Power Continues Sales Ramp as Q2 Revenue Rose 126% to $2.7M and FY 2019 First Six Months Revenue Rose 236% Versus Last Year
VISTA, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) — Flux Power Holdings, Inc. (OTCQB: FLUX), a developer of advanced lithium batteries for industrial applications including electric
Surge Provides an Update on Recent Gold Property Activity in BC and Reports on Additional Assay Results from Its Ontario Cobalt Exploration Program
VANCOUVER, British Columbia, Feb. 12, 2019 /PRNewswire/ — Surge Exploration Inc. (the “Company” or “Surge”) (TSX‐V: SUR) (OTCQB: SURJF), (FRA: DJ5C) is pleased to provide an update on various
Don Beaver, President of Probability & Statistics Inc , discusses their working relationship with Seafarer Exploration, Inc., the technical science to help with exploration, and block-chain cryptography.
CEO Coleman Smith of Green Zebra International Corp.Inc., discusses recent name/ticker symbol change, penetrating the wireless market with IOT, and looking to acquire revenue producing companies.
Pressure BioSciences Makes CBD Oil Water Soluble, Offering Solution to CBD Absorption Issue in Food & Beverages
New Video Demonstrates PBI’s Ultra Shear Technology and Potential Impact in CBD, Nutraceuticals, Foods, Cosmetics, and Other Oil-Based Markets SOUTH EASTON, MA / ACCESSWIRE / February
CARLSBAD, Calif., Feb. 13, 2019 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) (“ISCO” or “the Company”), a California-based clinical stage biotechnology company developing
MIAMI, Feb. 20, 2019 (GLOBE NEWSWIRE) — Progressive Care Inc. (OTCQB: RXMD), a personalized healthcare services and technology company, today announced further growth year-over-year in revenue and
Leronlimab (PRO 140) reduces by more than 98% human breast cancer metastasis in mouse xenografts for over 6 weeks
VANCOUVER, Washington, Feb. 20, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic
CytoDyn to Initiate 8 Pre-Clinical Animal Studies with Leronlimab (PRO 140) for Melanoma, Pancreatic, Breast, Prostate, Colon, Lung, Liver, and Stomach Cancer at an Estimated Cost of $1.5 million, which Could Lead to 8 Phase 2 Clinical Studies
VANCOUVER, Washington, Feb. 19, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody, leronlimab (PRO 140),
CEO Dr. Nader Pourhassan of CytoDyn Inc., talks about plans to eventually move up to the NASDAQ, revolutionizing cancer treatment, and approaching revenues by 2020.
Our Branding and Social Content Distributor Julie Kelley invites you to join her distributing our content from Uptick Newswire.
Contact Julie Kelley for more information: Julie.Uptick@gmail.com
Never Miss Anything
Subscribe to the Uptick Newswire Newsletter and receive small-cap stock investor news and research.
Host Connie Colella invites Micro Cap CEO’s to join her at Uptick Newswire’s Video Studio in Phoenix, AZ. for an informative, 1 on 1 interview about their respective companies.
Effective Immediately: Any Press Release submitted after 5:00PM (MTN) (8:00PM EST) there will be a $50 surcharge for rush orders. If you do not pay a $50 surcharge your press release will not be submitted.
The best nano & micro-cap news source.
Get Your Micro-Cap Company On The Air! Call (602) 441-3474 to find out more!